bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

International Journal of Cancer

Volumn 70, Issue 3, 1997, Pages 341-348

  Kyprianou, Natasha ^a,b,c   King, Edward D ^a   Bradbury, David ^a   Rhee, Juong G ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL LINE;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CLUSTERIN; DNA FRAGMENTATION; GENES, BCL-2; GLYCOPROTEINS; HUMANS; MALE; MOLECULAR CHAPERONES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION DOSAGE; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 0031045967     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I     Document Type: Article

References (45)

1. ALLAN, D.J., Radiation-induced apoptosis: its role in MAD CAT (mitosis-apoptosis-differentiation-calcium toxicity) scheme of cytotoxicity mechanisms. Int. J. Radiat. Biol., 62, 145-152 (1992).
2. BERGES, R.R., FURUYA, Y., REMINGTON, L., ENGLISH, H.F., JACKS, T. and ISAACS. J.T., Cell proliferation, DNA repair and p53 function are not required for programmed cell death of prostatic cells induced by androgen ablation. Proc. nat. Acad. Sci. (Wash.), 90, 8910-8914 (1993).
3. BISSONNETTE, R.P., ECHEVERRI, F., MAHBOUBI, A. and GREEN, D.R., Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359, 552-554 (1992).
4. BOISE, L.H., GONZALEZ-GARCIA, G.M., POSTEMA, C.E., DING, L.Y., LINDSTEN, T., TURKA, L.A., MAO, X.H., NUNEZ, G. and THOMPSON, C.B., Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608 (1993).
5. BORNER, M.M., MYERS, C.E., SARTOR, O., SEI, Y., TOKO, T., TREPEL, J.B. and SCHNEIDER, E., Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res., 55, 2122-2128 (1995).
6. BURNEY, T.L., ROCKOVE, S., EISEMAN, J., JACOBS, S.C. and KYPRIANOU, N., Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate, 25, 177-188 (1994).
7. CAMPOS, L., ROUAULT, J., SABIDO, O., ORIOL, P., ROUBI, N., VASSELON, C., ARCHIMBAUD, E., MAGAUD, J. and GUYOTAT, D., High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096 (1993).
8. CHEN, M., QUINTANS, J., FUKS, Z., THOMPSON, C., KUFE, D.W. and WEICHSELBAUM, R.R., Suppression of bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α and ceramide. Cancer Res., 55, 991-994 (1995).
9. COLOMBEL, M.C., SYMMANS, F., GIL, S., O'TOOLE, K.M., CHOPIN. D., BENSON, M., OLSSON, C., KORSMEYER, S. an BUTTYAN, R., Detection of apoptosis suppressing oncoprotein, bcl-2, in the hormone refractory human prostate cancer. Amer. J. Pathol., 143, 390-400 (1993).
10. ELKIND, M.M., Repair processes in the treatment and induction of cancer with radiation. Cancer, 65, 2165-2171 (1990).
11. FUKS, Z., PERSAUD, R.S., ALFIERI, A., MCLOUGHLIN, M., EHLEITER, D., SCHWARTZ, J.L., SEDDON, A.P., CORDON-CARDO, C. and HAIMOVITZ-FRIEDMAN, A., Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res., 54, 2582-2590 (1994).
12. FUKUNAGA-JOHNSON, N., RYAN, J.-J., WICHA, M., NUNEZ, G. and CLARKE, M.-F., Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation-induced cell death. Carcinogenesis, 16, 1761-1767 (1995).
13. FURUYA, Y., KRAJEWSKI, S., EPSTEIN, J.I., REED, J.C. and ISAACS, J.T., Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res., 2, 389-398 (1996).
14. GASPARINI, G., BARARESCHI, M., DOGLIONI, C., PALMA, P.D., MAURI, F.A., BORACHI, P., BEVILACQUA, P., CAFFO, O., MORELLI, L., VERDERIO, P., PEZZELLA, F. and HARRIS, A.L., Expression of bcl-2 predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1, 189-198 (1995).
15. HOCKENBERY, D.M., NUNEZ, G., MILLIMAN, C., SCHREIBER, R.D. and KORSMEYER, S.J., Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348, 334-336 (1990).
16. HOCKENBERY, D.M., OLTVAI, Z.N., YIN, X.M., MILLIMAN, C.L. and KORSMEYER, S.J., Bcl-2 functions in an anti-oxidant pathway to prevent apoptosis. Cell 75, 241-251 (1993).
17. KAMESAKI, A., KAMESAKI, H., JORGENSEN, T.J., TANIZAWA, A., POMMIER, Y. and COSSMAN, J., Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res., 53, 4251-4256 (1993).
18. KATOH, O., TAUCHI, H., KAWAISHI, K., KIMURA, A. and SATOW, Y., Expression of the vascular endothelial growth factor VEGF-receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res., 55, 5687-5692 (1995).
19. KRAJEWSKI, S., TANAKA, S., TAKAYAMA, S., SCHIBLER, M.J., FENTON, W. and REED, J.C., Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes. Cancer Res., 53, 4701-4714 (1993).
20. KUERBITZ, S.J., PLUNKETT, B.S., WALSH, W.V. and KASTAN, M.B., Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc. nat. Acad. Sci. (Wash.), 89, 7491-7495 (1992).
21. KYPRIANOU, N., Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J. Urol., 13, 299-303 (1994).
22. KYPRIANOU, N., BAINS, A.K. and JACOBS, S.C., Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate, 25, 66-75 (1994).
23. LEVINE, B., HUANG, Q., ISAACS, J.T., REED, J.C., GRIFFIN, D.E. and HARDWICK, J.M., Conversion of lytic to persistent infection by the bcl-2 cellular oncogene. Nature (Lond.), 361, 739-742 (1993).
24. LING, C.C., GUO, M., CHEN, C.H.C. and DELOHERY, T., Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Res., 55, 5207-5212 (1995).
25. LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A. and JACKS, T., p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362, 847-849 (1993).
26. MCDONNELL, T.J., TRONCOSO, P., BRISBAY, S.M., LOGOTHETIS, C., CHUNG, L.W.K., HSIEH, J.-T., TU, S.-M. and CAMPBELL, M.L., Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52, 6940-6944 (1992).
27. MCILWRATH, A.J., VASEY, P.A., ROSS, G.M. and BROWN, R., Cell cycle-arrest and radiosensitivity of human tumor cell lines. Dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718-3722 (1994).
28. MIYASHITA, T. and REED, J.C., Bcl-2 gene transfer increases relative resistance of S49.1 and WE H17.2 lymphoid cells to cell death and DNA fragmentation induced by glucococorticoids and chemotherapeutic drugs. Cancer Res., 52, 5407-5411 (1992).
29. 1 phase arrest and p53 function in human tumor cells. Cancer Res., 55, 1842-1846 (1995).
30. OLTVAI, Z.N., MILLIMAN, C.L. and KORSMEYER, S.J., Bcl-2 heterodimerizes in vivo with a conserved homologue BAX that accelerates cell death. Cell, 74, 609-619 (1993).
31. PIETENPOL, J.A., PAPADOPOULOS, N., MARKOWITZ, S., WILSON, J.K., KINZLER, K.W. and VOGELSTEIN, B., Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res., 54, 3714-3717 (1994).
32. RAFFO, A.J., PERLMAN, H., CHEN, M.-W., DAY, M.L., STREITMAN, J.C.S. and BUTTYAN, R., Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55, 4438-4445 (1995).
33. REED, J.C., Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124, 1-6 (1994).
34. RUDOLZ, M.S., BERNHARD, E.J., KAO, G.D., MURCHEL, R.J. and MCKENNA, W.G., Apoptosis, cell cycle kinetics and clonogenic survival in a solid tumor model system expressing bcl-2 [Abstract]. Proc. Amer. Assoc. Cancer Res., 37, 602 (1996).
35. SCHELLHAMER, P.F., Radiation therapy for localized prostate cancer: what has been and still remains to be learned. Monogr. Urol., 15, (1994).
36. SENTMAN, C.L., SHUTTER, J.R., HOCKENBERY, D., KANAGAWA, O. and KORSMEYER, S.J., Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879-888 (1991).
37. SKLAR, G.N., EDDY, H.A., JACOBS, S.C. and KYPRIANOU, N., Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J. Urol., 150, 1526-1532 (1993).
38. SOLDATENKOV, V.A., PRASAD, S., NOTARIO, V. and DRITSCHILO, A., Radiation-induced apoptosis of Ewing's sarcoma cells: DNA fragmentation and proteolysis of poly (ADP-ribose) polymerase. Cancer Res., 55, 4240-4242 (1995).
39. STEPHENS, L.C., HUNTER, N.R., ANG, K.K., MILAS, L. and MEYN, R.E., Development of apoptosis in irradiated murine tumors as a function of time and dose. Rad. Res., 135, 75-80 (1993).
40. THOMPSON, C.B., Apoptosis in pathogenesis and treatment of disease. Science, 267, 1456-1462 (1995).
41. TSUJIMOTO, Y., FINGER, L.R., YUNIS, J., NOWELL, P.C. and CROCE, C.M., Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science, 226, 1097-1099 (1984).
42. WALTON, M.I., WHYSONG, D., O'CONNOR, P.M., HOCKENBERY, D., KORSMEYER, S.J. and KOHN, K.W., Constitutive expression of human bcl-2 modulates nitrogen mustard and campthothecin induced apoptosis. Cancer Res., 53, 1853-1861 (1993).
43. WINGO, P.A., TONG, T. and BOLDEN, S., Cancer statistics. CA Cancer J. Clin., 45, 8-30 (1995).
44. YIN, D.X. and SCHIMKE, R.T., bcl-2 expression delays drug-induced apotosis but does not increase clonogenic survival after drug treatment in HeLa cells. CancerRes., 55, 4922-4928 (1995).
45. ZELEFSKY, M.J., LEIBEL. S.A., BURMAN, C.M., KUTCHER, G.J., HARRISON, A., HAPPERSETT, L. and FUKS, Z., Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic disease treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 29, 755-761 (1994).